V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Esperion Therapeutics Executive Compensation (FY25)

ESPR · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): June 1, 2026
151 figures on this page: 141 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Total compensation for Sheldon Koenig, President and Chief Executive Officer, came to $3,535,512 in fiscal 2025, and compared with the $3,175,240 reported for fiscal 2024, Koenig's total was 11.3% higher. Figures cover fiscal 2024 through fiscal 2025. The company reported 3 named executive officers for fiscal 2025. The say-on-pay proposal drew 73.3% of votes cast for or against in favor at the meeting held May 28, 2026 for fiscal 2025.
Chief executive, fiscal 2025
◇
Sheldon Koenig
Latest say-on-pay support
=
May 28, 2026
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sheldon Koenig: $3,175,240 → $3,535,512 (11.3% higher)
Say-on-pay support: 72.6% → 73.3% (0.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Esperion Therapeutics' chief executive and what were they paid?
Total compensation for Sheldon Koenig, President and Chief Executive Officer, came to $3,535,512 in fiscal 2025. Compared with the $3,175,240 reported for fiscal 2024, Koenig's total was 11.3% higher.
What was Esperion Therapeutics' say-on-pay result?
The say-on-pay proposal drew 73.3% of votes cast for or against in favor at the meeting held May 28, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sheldon Koenig
President and Chief Executive Officer
◇—◇◇◇—◇◇
John Harlow
Chief Commercial Officer
◇◇◇◇——◇◇
Benjamin Halladay
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Benjamin HalladayOTHER——————◇
Benjamin HalladayOPTION——————◇
John HarlowOTHER——————◇
John HarlowOPTION——————◇
Sheldon KoenigOPTION——————◇
Sheldon KoenigOTHER——————◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sheldon KoenigOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Benjamin HalladayOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
John HarlowOption◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
J. Martin Carroll
Board chair
◇◇◇———◇
Seth H.Z. Fischer
◇◇◇———◇
Tracy M. Woody
◇—◇———◇
Jay P. Shepard
◇◇◇———◇
Stephen Rocamboli
◇◇◇———◇
Robert E. Hoffman
◇◇◇———◇
Nicole Vitullo
◇—◇———◇
Antonio M. Gotto, Jr., M.D., D.Phil
◇————◇◇
Alan Fuhrman
◇—————◇
Craig Thompson
◇—◇———◇
Sheldon L. Koenig served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 28, 2026=◇◇◇
2024May 29, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2020May 27, 2021=◇◇◇
2019May 28, 2020=◇◇◇
2018May 29, 2019=◇◇◇
2017May 23, 2018=◇◇◇
2016April 17, 2017=◇◇◇
2015June 9, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Esperion Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Esperion Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Esperion Therapeutics' disclosed peer group is defensible, who names Esperion Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
151 figures on this page: 141 cited to the filing that reported them, 10 calculated from figures it prints.
141 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001628280-26-039518
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-025499
    2025 Director Compensation Table · 2025 Summary Compensation Table · EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · Outstanding Equity Awards at 2025 Fiscal Year-End Table
  3. 0001628280-25-028820
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-018229
    2024 Summary Compensation Table
  5. 0001628280-24-025418
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001628280-23-022276
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001628280-21-011340
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-20-067802
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-19-032758
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001104659-18-036428
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-17-024913
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-16-127351
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Esperion Therapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/ESPR (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Esperion Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy